195 related articles for article (PubMed ID: 28432616)
21. Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2.
Spirina L; Yurmazov Z; Usynin E; Kondakova I; Ladutko E; Choynzonov E
Curr Issues Mol Biol; 2021 Sep; 43(2):1072-1080. PubMed ID: 34563045
[TBL] [Abstract][Full Text] [Related]
22. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.
Erlmeier F; Steffens S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Ivanyi P;
Clin Genitourin Cancer; 2021 Feb; 19(1):53-59.e1. PubMed ID: 32778505
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated protein 4 expressions together with clinicopathological findings in clear cell, papillary, and chromophobe types of renal cell carcinoma.
Inceman M; Toyran T; Bayazit Y; Izol V; Erdogan S
Pol J Pathol; 2022; 73(3):181-190. PubMed ID: 36734432
[TBL] [Abstract][Full Text] [Related]
24. Kidney cancer: PDL1 as a biomarker in high-risk RCC.
Kelsey R
Nat Rev Urol; 2018 Apr; 15(4):202. PubMed ID: 29434371
[No Abstract] [Full Text] [Related]
25. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8.
Ikeda J; Ohe C; Yoshida T; Ohsugi H; Sugi M; Tsuta K; Kinoshita H
Anticancer Res; 2021 Sep; 41(9):4577-4586. PubMed ID: 34475086
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
[TBL] [Abstract][Full Text] [Related]
28. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.
Ascierto ML; McMiller TL; Berger AE; Danilova L; Anders RA; Netto GJ; Xu H; Pritchard TS; Fan J; Cheadle C; Cope L; Drake CG; Pardoll DM; Taube JM; Topalian SL
Cancer Immunol Res; 2016 Sep; 4(9):726-33. PubMed ID: 27491898
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma.
Sorokina M; Stupichev D; Lyu Y; Ramachandran A; Miheecheva N; Brown JH; Nomie K; Postovalova E; Bagaev A; Tsiper M; Hsieh JJ
Clin Genitourin Cancer; 2021 Dec; 19(6):e374-e381. PubMed ID: 34389275
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
31. Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?
McClanahan F; Sharp TG; Gribben JG
Haematologica; 2016 Oct; 101(10):1144-1158. PubMed ID: 27694502
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].
Campedel L; Seisen T; Cussenot O; Comperat E; Varinot J; Rouprêt M; Cancel-Tassin G
Prog Urol; 2018 Dec; 28(16):900-905. PubMed ID: 30219646
[TBL] [Abstract][Full Text] [Related]
33. PD-1 Expression and its Correlation With Prognosis in Clear Cell Renal Cell Carcinoma.
Kim MH; Ko GH; Lee JH; Lee JS; Kim DC; Yang JW; An HJ; Na JM; Song DH
In Vivo; 2021; 35(3):1549-1553. PubMed ID: 33910834
[TBL] [Abstract][Full Text] [Related]
34. Variability of PD-L1 expression in mastocytosis.
Hatch EW; Geeze MB; Martin C; Salama ME; Hartmann K; Eisenwort G; Blatt K; Valent P; Gotlib J; Lee JH; Chen L; Ward HH; Lidke DS; George TI
Blood Adv; 2018 Feb; 2(3):189-199. PubMed ID: 29378725
[TBL] [Abstract][Full Text] [Related]
35. Impact of PD-L1 Protein Expression on Renal Cell Carcinoma Histo-differentiation.
Tziakou P; Theodoropoulos G; Tsiambas E; Zizi-Sermpetzoglou A; Peschos D; Mastronikoli S; Thomopoulou G; Thymara E; Kavantzas N; Lazaris AC
Anticancer Res; 2021 Aug; 41(8):3809-3813. PubMed ID: 34281840
[TBL] [Abstract][Full Text] [Related]
36. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
37. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
López JI; Pulido R; Cortés JM; Angulo JC; Lawrie CH
Pathol Res Pract; 2018 Aug; 214(8):1110-1114. PubMed ID: 29910061
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression in papillary renal cell carcinoma.
Motoshima T; Komohara Y; Ma C; Dewi AK; Noguchi H; Yamada S; Nakayama T; Kitada S; Kawano Y; Takahashi W; Sugimoto M; Takeya M; Fujimoto N; Oda Y; Eto M
BMC Urol; 2017 Jan; 17(1):8. PubMed ID: 28086852
[TBL] [Abstract][Full Text] [Related]
39. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
[TBL] [Abstract][Full Text] [Related]
40. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma.
Krambeck AE; Dong H; Thompson RH; Kuntz SM; Lohse CM; Leibovich BC; Blute ML; Sebo TJ; Cheville JC; Parker AS; Kwon ED
Clin Cancer Res; 2007 Mar; 13(6):1749-56. PubMed ID: 17363528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]